| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | C1QR1; C1qRP; CDw93; ECSM3; MXRA4; C1qR(P); dJ737E23.1 |
| Entrez GeneID | 22918 |
| clone | 1A10E10 |
| WB Predicted band size | 68.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD93 (AA: 474-535) expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于CD93抗体的3篇代表性文献(均为虚构示例，供参考)：
---
1. **文献名称**：CD93-targeted antibody inhibits tumor angiogenesis and enhances chemotherapy efficacy
**作者**：Zhang Y, et al.
**摘要**：本研究开发了一种靶向CD93的单克隆抗体，通过阻断CD93与整合素相互作用抑制肿瘤血管生成。动物实验显示该抗体联合化疗可显著抑制实体瘤生长，提示其在抗肿瘤治疗中的潜力。
2. **文献名称**：CD93 modulates macrophage polarization via TGF-β signaling in inflammatory diseases
**作者**：Lee S, et al.
**摘要**：文章阐明CD93抗体通过调控巨噬细胞向M2型极化，减轻炎症反应。实验表明CD93是TGF-β通路的关键调节因子，其抗体在治疗自身免疫性疾病中具有应用前景。
3. **文献名称**：CD93 as a biomarker for endothelial dysfunction in atherosclerosis
**作者**：Garcia-Robles A, et al.
**摘要**：研究发现CD93在动脉粥样硬化患者血管内皮细胞中高表达。使用特异性抗体阻断CD93可减少斑块形成，提示其作为内皮功能障碍的生物标志物和治疗靶点。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“CD93 antibody therapeutic”或“CD93 biomarker”。近年研究多聚焦于其在肿瘤血管靶向治疗和免疫微环境调控中的作用。
CD93. a type I transmembrane glycoprotein, is primarily expressed on vascular endothelial cells and immune cells like monocytes and neutrophils. It belongs to the C-type lectin domain family, featuring an N-terminal lectin-like domain, epidermal growth factor (EGF)-like repeats, a mucin-rich region, and a short cytoplasmic tail. CD93 plays a critical role in cell adhesion, migration, and angiogenesis, particularly in stabilizing tumor vasculature through interactions with extracellular matrix proteins like multimerin-2. Its involvement in immune regulation includes modulating phagocytosis and inflammatory responses.
CD93 antibodies are tools for detecting CD93 expression in research and therapeutic contexts. In cancer studies, anti-CD93 agents inhibit tumor angiogenesis by disrupting endothelial cell interactions, showing promise in preclinical models. Additionally, CD93 antibodies are explored in inflammatory and vascular diseases due to their role in leukocyte recruitment and endothelial activation. Challenges remain in optimizing specificity and minimizing off-target effects. Current research focuses on antibody-drug conjugates and blocking antibodies, with several candidates in early-stage development for oncology applications. These antibodies hold potential as biomarkers or targeted therapies but require further validation in clinical settings.
×
